34 related articles for article (PubMed ID: 26709239)
1. Prediction of disease recurrence in patients after complete pancreatic NET (PanNET) G2 resection.
Olearska H; Sowa-Staszczak A; Morawiec-Sławek K; Kurzyńska A; Kolasa M; Tkacz E; Szumińska M; Hubalewska-Dydejczyk A; Opalinska M
Endokrynol Pol; 2024; 75(1):102-108. PubMed ID: 38497396
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic Neuroendocrine Tumors: an Update.
Paniccia A; Edil BH; Schulick RD
Indian J Surg; 2015 Oct; 77(5):395-402. PubMed ID: 26722203
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients.
Shiba S; Morizane C; Hiraoka N; Sasaki M; Koga F; Sakamoto Y; Kondo S; Ueno H; Ikeda M; Yamada T; Shimada K; Kosuge T; Okusaka T
Pancreatology; 2016; 16(1):99-105. PubMed ID: 26718527
[TBL] [Abstract][Full Text] [Related]
4. Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
Genç CG; Falconi M; Partelli S; Muffatti F; van Eeden S; Doglioni C; Klümpen HJ; van Eijck CHJ; Nieveen van Dijkum EJM
Ann Surg Oncol; 2018 Aug; 25(8):2467-2474. PubMed ID: 29789972
[TBL] [Abstract][Full Text] [Related]
5. Impact of Regional Metastasis on Survival for Patients with Nonfunctional Pancreatic Neuroendocrine Tumors: A Systematic Review.
Clarke CN; Ward E; Henry V; Nimmer K; Phan A; Evans DB
Ann Surg Oncol; 2024 Apr; ():. PubMed ID: 38652199
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Risk Factors for Distant and Lymph Node Metastasis of Pancreatic Neuroendocrine Tumors.
Molasy B; Zemła P; Mrowiec S; Grudzińska E; Kuśnierz K
Ther Clin Risk Manag; 2022; 18():745-752. PubMed ID: 35937972
[TBL] [Abstract][Full Text] [Related]
7. Serum Inflammation-based Scores in Endocrine Tumors.
Marques P; de Vries F; Dekkers OM; Korbonits M; Biermasz NR; Pereira AM
J Clin Endocrinol Metab; 2021 Sep; 106(10):e3796-e3819. PubMed ID: 33837783
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor.
Xu SS; Xu HX; Wang WQ; Li S; Li H; Li TJ; Zhang WH; Liu L; Yu XJ
World J Gastroenterol; 2019 Nov; 25(41):6248-6257. PubMed ID: 31749595
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.
Lee L; Ito T; Jensen RT
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1029-1050. PubMed ID: 31738624
[No Abstract] [Full Text] [Related]
10. Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.
Zhou Y; Li D; Lin Y; Yu M; Lu X; Jian Z; Na N; Hou B
Onco Targets Ther; 2018; 11():2489-2496. PubMed ID: 29760558
[TBL] [Abstract][Full Text] [Related]
11. Clinical Usefulness of
Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
[TBL] [Abstract][Full Text] [Related]
12. Risk-factors for nodular hyperplasia of parathyroid glands in sHPT patients.
Jäger MD; Serttas M; Beneke J; Müller JA; Schrem H; Kaltenborn A; Ramackers W; Ringe BP; Gwiasda J; Tränkenschuh W; Klempnauer J; Scheumann GFW
PLoS One; 2017; 12(10):e0186093. PubMed ID: 29040300
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems.
Benetatos N; Hodson J; Marudanayagam R; Sutcliffe RP; Isaac JR; Ayuk J; Shah T; Roberts KJ
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):169-175. PubMed ID: 29576279
[TBL] [Abstract][Full Text] [Related]
15. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
16. Standard pre- and postoperative determination of chromogranin a in resectable non-functioning pancreatic neuroendocrine tumors--diagnostic accuracy: NF-pNET and low tumor burden.
Jilesen AP; Busch OR; van Gulik TM; Gouma DJ; Nieveen van Dijkum EJ
Dig Surg; 2014; 31(6):407-14. PubMed ID: 25572908
[TBL] [Abstract][Full Text] [Related]
17. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review.
Pezzilli R; Partelli S; Cannizzaro R; Pagano N; Crippa S; Pagnanelli M; Falconi M
Adv Med Sci; 2016 Mar; 61(1):147-53. PubMed ID: 26774266
[TBL] [Abstract][Full Text] [Related]
18. Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms.
Kaltenborn A; Matzke S; Kleine M; Krech T; Ramackers W; Vondran FW; Klempnauer J; Bektas H; Schrem H
J Surg Oncol; 2016 Feb; 113(2):194-202. PubMed ID: 26709239
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
